Reported Standalone quarterly numbers for Sun Pharmaceutical Industries are:Net Sales at Rs 5,948.22 crore in March 2023 up 48.45% from Rs. 4,006.88 crore in March 2022.
Quarterly Net Loss at Rs. 1,020.82 crore in March 2023 up 20.63% from Rs. 1,286.21 crore in March 2022.
EBITDA stands at Rs. 2,480.95 crore in March 2023 up 90.81% from Rs. 1,300.25 crore in March 2022.
Sun Pharma shares closed at 944.70 on May 25, 2023 (BSE) and has given -8.62% returns over the last 6 months and 3.79% over the last 12 months.
| Sun Pharmaceutical Industries | | Standalone Quarterly Results | in Rs. Cr. |
|
| Mar'23 | Dec'22 | Mar'22 | | Net Sales/Income from operations | 5,800.85 | 4,549.90 | 3,988.22 | | Other Operating Income | 147.37 | 95.85 | 18.66 | | Total Income From Operations | 5,948.22 | 4,645.75 | 4,006.88 | | EXPENDITURE | | Consumption of Raw Materials | 1,189.86 | 1,248.76 | 1,286.24 | | Purchase of Traded Goods | 262.36 | 267.51 | 237.84 | | Increase/Decrease in Stocks | -132.64 | -9.66 | -150.13 | | Power & Fuel | -- | -- | -- | | Employees Cost | 529.05 | 526.24 | 497.94 | | Depreciation | 411.98 | 430.44 | 354.14 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 1,738.94 | 1,613.52 | 1,135.15 | | P/L Before Other Inc. , Int., Excpt. Items & Tax | 1,948.67 | 568.94 | 645.70 | | Other Income | 120.30 | 68.03 | 300.41 | | P/L Before Int., Excpt. Items & Tax | 2,068.97 | 636.97 | 946.11 | | Interest | 161.45 | 130.89 | 91.19 | | P/L Before Exceptional Items & Tax | 1,907.52 | 506.08 | 854.92 | | Exceptional Items | -2,937.79 | -- | -1,654.96 | | P/L Before Tax | -1,030.27 | 506.08 | -800.04 | | Tax | -9.45 | 19.35 | 486.17 | | P/L After Tax from Ordinary Activities | -1,020.82 | 486.73 | -1,286.21 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | -1,020.82 | 486.73 | -1,286.21 | | Equity Share Capital | 239.93 | 239.93 | 239.93 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | -4.30 | 2.00 | -5.40 | | Diluted EPS | -4.30 | 2.00 | -5.40 | | EPS After Extra Ordinary | | Basic EPS | -4.30 | 2.00 | -5.40 | | Diluted EPS | -4.30 | 2.00 | -5.40 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
